Decoy Therapeutics (DCOY) Current Assets (2014 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Current Assets of $8.4 million for Q1 2026, up 262.57% year-over-year from $2.3 million in Q1 2025, and down 23.92% quarter-over-quarter from $11.0 million in Q4 2025.
Decoy Therapeutics (DCOY) Current Assets (2014 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Current Assets for 13 consecutive years, with $8.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 262.57% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 262.57% YoY), while the FY2025 annual figure was $11.0 million, up 267.7% from the prior year.
- Current Assets retreated to $8.4 million in Q1 2026 per DCOY's latest filing, from $11.0 million in the prior quarter.
- Across five years, Current Assets topped out at $24.9 million in Q1 2022 and bottomed at $1.4 million in Q2 2025.
- Historically, Current Assets has averaged $9.5 million across 5 years, with a median of $8.3 million in 2023.
- Annual changes were most pronounced in 2024 — Current Assets tumbled 70.61% — and 2025, when it jumped 267.7%.
- Decoy Therapeutics' Current Assets stood at $14.5 million in 2022, then plunged by 55.1% to $6.5 million in 2023, then slumped by 54.18% to $3.0 million in 2024, then surged by 267.7% to $11.0 million in 2025, then retreated by 23.92% to $8.4 million in 2026.
- Business Quant data shows DCOY's Current Assets at $8.4 million in Q1 2026, $11.0 million in Q4 2025, and $6.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | 8.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.57 Mn |
| Mar 31, 2026 | 8.36 Mn |
| Dec 31, 2025 | 10.99 Mn |
| Sep 30, 2025 | 6.06 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Jun 30, 2024 | 3.51 Mn |
| Mar 31, 2024 | 4.83 Mn |
| Dec 31, 2023 | 6.52 Mn |
| Sep 30, 2023 | 8.32 Mn |
| Jun 30, 2023 | 11.96 Mn |
| Mar 31, 2023 | 9.94 Mn |
| Dec 31, 2022 | 14.52 Mn |
| Sep 30, 2022 | 17.97 Mn |
| Jun 30, 2022 | 23.02 Mn |
| Mar 31, 2022 | 24.86 Mn |
| Dec 31, 2021 | 30.16 Mn |
| Sep 30, 2021 | 35.18 Mn |